Fondazione Telethon
Len Pattenden is an accomplished professional in the biopharmaceutical industry with extensive experience in various leadership roles. Currently serving as the Head of CMC at Fondazione Telethon, Len has previously held positions such as Managing Director at CMC Biopharma Ltd and Chief Operating Officer at Ascend Gene & Cell Therapies. Len also contributed significantly to Cancer Research UK as the Head of Biotherapeutic Development & Drug Supply and led the Vector Upstream Development Group at Adaptimmune. Len holds a Doctor of Philosophy (PhD) in Pharmaceutics and Drug Design from Queensland University of Technology, earned between 1997 and 2004.
This person is not in the org chart
This person is not in any offices
Fondazione Telethon
Founded in 1990, Telethon Italy is one of the biggest biomedical charity in Italy, whose mission is to advance biomedical research towards the diagnosis, cure and prevention of muscular dystrophies and other human genetic diseases. Telethon Italy focuses on scientific research and does not offer healthcare, material assistance to patients and families or advocacy. Since 1991, Telethon Italy has invested 394 million Euros in research and funded 2,477 research projects on more than 445 human genetic diseases, which range from basic research to clinical trials.